iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management

We aimed to develop a user-centered, web-based, decision support tool for breast cancer risk assessment and personalized risk management. Using a novel model choice algorithm, iPrevent® selects one of two validated breast cancer risk estimation models (IBIS or BOADICEA), based on risk factor data entered by the user. Resulting risk estimates are presented in simple language and graphic formats for easy comprehension. iPrevent® then presents risk-adapted, evidence-based, guideline-endorsed management options. Development was an iterative process with regular feedback from multidisciplinary experts and consumers. To verify iPrevent®, risk factor data for 127 cases derived from the Australian Breast Cancer Family Study were entered into iPrevent®, IBIS (v7.02), and BOADICEA (v3.0). Consistency of the model chosen by iPrevent® (i.e., IBIS or BOADICEA) with the programmed iPrevent® model choice algorithm was assessed. Estimated breast cancer risks from iPrevent® were compared with those attained directly from the chosen risk assessment model (IBIS or BOADICEA). Risk management interventions displayed by iPrevent® were assessed for appropriateness. Risk estimation model choice was 100 % consistent with the programmed iPrevent® logic. Discrepant 10-year and residual lifetime risk estimates of >1 % were found for 1 and 4 cases, respectively, none was clinically significant (maximal variation 1.4 %). Risk management interventions suggested by iPrevent® were 100 % appropriate. iPrevent® successfully integrates the IBIS and BOADICEA risk assessment models into a decision support tool that provides evidence-based, risk-adapted risk management advice. This may help to facilitate precision breast cancer prevention discussions between women and their healthcare providers.

[1]  R. P. Fishburne,et al.  Derivation of New Readability Formulas (Automated Readability Index, Fog Count and Flesch Reading Ease Formula) for Navy Enlisted Personnel , 1975 .

[2]  Shannon K. McDonnell,et al.  EFFICACY OF BILATERAL PROPHYLACTIC MASTECTOMY IN WOMEN WITH A FAMILY HISTORY OF BREAST CANCER , 1999 .

[3]  John L Hopper,et al.  Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. , 2003, Journal of the National Cancer Institute.

[4]  L. J. Schelven,et al.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group , 2004 .

[5]  Stephen W Duffy,et al.  A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.

[6]  T. Rebbeck,et al.  Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[8]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007 .

[9]  Liang Y Liu,et al.  Verification and validation of a project collaboration tool , 2008 .

[10]  J. Hopper,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions , 2008, British Journal of Cancer.

[11]  Isaac S Kohane,et al.  Tectonic shifts in the health information economy. , 2008, The New England journal of medicine.

[12]  H. Nelson,et al.  Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer , 2009, Annals of Internal Medicine.

[13]  Susan M. Domchek,et al.  Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers , 2009, Journal of the National Cancer Institute.

[14]  L. Lostumbo,et al.  Prophylactic mastectomy for the prevention of breast cancer. , 2010, Cochrane Database of Systematic Reviews.

[15]  D. Evans,et al.  Assessing women at high risk of breast cancer: a review of risk assessment models. , 2010, Journal of the National Cancer Institute.

[16]  R. Peto,et al.  The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010 , 2011, British Journal of Cancer.

[17]  D M Parkin,et al.  16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010 , 2011, British Journal of Cancer.

[18]  E. Thompson,et al.  BRCA and beyond: a genome-first approach to familial breast cancer risk assessment. , 2011, Discovery medicine.

[19]  R. Sargent.  Verification and validation of simulation models , 2011, Proceedings of the 2011 Winter Simulation Conference (WSC).

[20]  Sylvia K Plevritis,et al.  Online tool to guide decisions for BRCA1/2 mutation carriers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Suzanne K. Linder,et al.  Presenting probabilities [Chapter C] , 2012 .

[22]  B. Karlan,et al.  Oophorectomy after Menopause and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[23]  G. Giles,et al.  Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre , 2013, British Journal of Cancer.

[24]  J. Hopper,et al.  Preventing breast and ovarian cancers in high‐risk BRCA1 and BRCA2 mutation carriers , 2013, The Medical journal of Australia.

[25]  J. Cuzick,et al.  Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G. Glendon,et al.  A focus group study on breast cancer risk presentation: one format does not fit all , 2012, European Journal of Human Genetics.

[27]  J. Emery,et al.  Assessing and managing breast cancer risk: clinicians' current practice and future needs. , 2014, Breast.

[28]  D. Easton,et al.  BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface , 2013, British Journal of Cancer.

[29]  A. Whittemore,et al.  Practical Problems With Clinical Guidelines for Breast Cancer Prevention Based on Remaining Lifetime Risk , 2015, Journal of the National Cancer Institute.

[30]  Jane E. Carpenter,et al.  Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants , 2015, JNCI Journal of the National Cancer Institute.

[31]  P. Narula.  MAMMOGRAPHIC DENSITY AND THE RISK AND DETECTION OF BREAST CANCER , 2016 .

[32]  A. Whittemore,et al.  Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC) , 2015, International journal of epidemiology.

[33]  J. Emery,et al.  Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease? , 2016, Australian journal of primary health.